ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (L...

Full description

Bibliographic Details
Main Authors: Tatiana Galicia-Carmona, Eder Arango-Bravo, Juan a Serrano-Olvera, Celia Flores-de La Torre, Ivan Cruz-Esquivel, Ricardo Villalobos-Valencia, Andrés Morán-Mendoza, Denisse Castro-Eguiluz, Lucely Cetina-Pérez
Format: Article
Language:English
Published: Taylor & Francis Group 2021-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immunotherapy
adxs11-001
cervical cancer
listeria monocytogenes vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2021.1893036

Internet

http://dx.doi.org/10.1080/21645515.2021.1893036

Similar Items